aspirin and Chagas Cardiomyopathy
aspirin has been researched along with Chagas Cardiomyopathy in 4 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Chagas Cardiomyopathy: A disease of the CARDIAC MUSCLE developed subsequent to the initial protozoan infection by TRYPANOSOMA CRUZI. After infection, less than 10% develop acute illness such as MYOCARDITIS (mostly in children). The disease then enters a latent phase without clinical symptoms until about 20 years later. Myocardial symptoms of advanced CHAGAS DISEASE include conduction defects (HEART BLOCK) and CARDIOMEGALY.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on the risk-benefit analysis, warfarin prophylaxis for cardioembolic stroke in Chagas' disease is recommended for patients with a score of 4-5 points, in whom the risk of CE overweighs the risk of a major bleeding." | 3.74 | Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. ( Freitas, GR; Hasslocher-Moreno, A; Sousa, AS; Xavier, SS, 2008) |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Molina-Berríos, A | 1 |
| Campos-Estrada, C | 1 |
| Lapier, M | 1 |
| Duaso, J | 1 |
| Kemmerling, U | 1 |
| Galanti, N | 1 |
| Ferreira, J | 1 |
| Morello, A | 1 |
| López-Muñoz, R | 1 |
| Maya, JD | 1 |
| Ogata, H | 1 |
| Teixeira, MM | 1 |
| Sousa, RC | 1 |
| Silva, MV | 1 |
| Correia, D | 1 |
| Rodrigues Junior, V | 1 |
| Levy, BD | 1 |
| Rogério, Ade P | 1 |
| Sousa, AS | 1 |
| Xavier, SS | 1 |
| Freitas, GR | 1 |
| Hasslocher-Moreno, A | 1 |
| de Bracco, MM | 1 |
| Sterin-Borda, L | 1 |
| Fink, S | 1 |
| Finiasz, M | 1 |
| Borda, E | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas[NCT05519046] | 60 participants (Anticipated) | Interventional | 2022-05-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Other Studies
4 other studies available for aspirin and Chagas Cardiomyopathy
| Article | Year |
|---|---|
Protection of vascular endothelium by aspirin in a murine model of chronic Chagas' disease.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Chagas Cardiomyopathy; Chronic Disease; Disease Models, | 2013 |
Effects of aspirin-triggered resolvin D1 on peripheral blood mononuclear cells from patients with Chagas' heart disease.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Count; Cell Proliferation; | 2016 |
Prevention strategies of cardioembolic ischemic stroke in Chagas' disease.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Chagas Cardiomyopathy; Epidemiologic Methods; Female; Hemor | 2008 |
Stimulatory effect of lymphocytes from Chagas' patients on spontaneously beating rat atria.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Aspirin; Catechols; Chagas Cardiomyopathy; Chagas Disease; | 1984 |